Table 1.
Author | Case (age/gender) | Received therapy | Outcome | |
---|---|---|---|---|
rFVIIa | Esper et al., 20143 | 37 F | MTPx3, RTX, rFVIIa | Survived |
Alabed, 201442 | 37 F | MTPx3, CPM, rFVIIa | Survived | |
Pathak et al., 201541 | 2 cases | Steroids, plasmapheresis, rFVIIa | Both Survived | |
ECMO | Wang et al., 201830 | 3 cases | MTP, CPM, plasmapheresis, ECMO | All three died |
Pais F et al., 201728 | 38 F | MTP, plasmapheresis, ECMO | Survived | |
Pacheco Claudio et al., 201448 | 33 F | MTP, CPM, ECMO | Died | |
36 M | MTP, CPM, ECMO | Survived | ||
Kimura et al., 201549 | 14 F | MTP, CPM, plasmapheresis, IVIG, ECMO | Survived | |
Patel et al., 201450 | 28 F | MTP, CPM, RTX ECMO | Survived | |
MSCT | Liang J et al., 201243 | 19 F | MTP, IVIG, UC-MSCT | Survived |
Shi D et al., 201244 | 4 cases | Several regimens + UC-MSCT | All four improved |
F: female; M: male; rFVIIa: Recombinant activated clotting factor VII; MTP: methylprednisolone; RTX: rituximab; CPM: cyclophosphamide; ECMO: extracorporeal membrane oxygenation; IVIG: Intravenous immunoglobulin; UC-MSCT: umbilical cord mesenchymal stem cell transplantation.